Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Adma Biologics (ADMA) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Adma Biologics (ADMA) over the last 13 years, with Q3 2025 value amounting to $1.3 million.

  • Adma Biologics' Other Operating Expenses rose 2488.08% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year increase of 2150.84%. This contributed to the annual value of $4.6 million for FY2024, which is 715.43% down from last year.
  • As of Q3 2025, Adma Biologics' Other Operating Expenses stood at $1.3 million, which was up 2488.08% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Adma Biologics' Other Operating Expenses ranged from a high of $5.3 million in Q4 2022 and a low of $646000.0 during Q3 2023
  • For the 5-year period, Adma Biologics' Other Operating Expenses averaged around $2.4 million, with its median value being $1.5 million (2023).
  • Per our database at Business Quant, Adma Biologics' Other Operating Expenses soared by 11057.56% in 2021 and then tumbled by 8717.82% in 2023.
  • Adma Biologics' Other Operating Expenses (Quarter) stood at $4.3 million in 2021, then increased by 23.16% to $5.3 million in 2022, then tumbled by 83.44% to $872000.0 in 2023, then surged by 49.31% to $1.3 million in 2024, then grew by 0.61% to $1.3 million in 2025.
  • Its Other Operating Expenses was $1.3 million in Q3 2025, compared to $1.2 million in Q2 2025 and $1.3 million in Q1 2025.